Mechanisms of chemoresistance in epithelial ovarian cancer: recent discoveries

References

• McGuire WP 3rd, Markman M. Primary ovarian cancer chemotherapy: current standards of care. Br. J. Cancer89(Suppl. 3), S3–S8 (2003).
   PubMed Web of Science ®Google Scholar
• Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Perez JM. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med. Chem.7, 3–18 (2007).
   PubMed Web of Science ®Google Scholar
• Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer4, 253–265 (2004).
   PubMed Web of Science ®Google Scholar
• Blagden S, Gabra H. Future directions in the management of epithelial ovarian cancer. Future Oncol.4, 403–411 (2008).
   PubMedGoogle Scholar
• Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci.99, 653–658 (2008).
   PubMed Web of Science ®Google Scholar
• Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat. Rev. Genet.9, 102–114 (2008).
   PubMed Web of Science ®Google Scholar
• Mezzanzanica D, Bagnoli M, De Cecco L, Valeri B, Canevari S. Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. Int. J. Biochem. Cell Biol.42, 1262–1272 (2010).
   PubMed Web of Science ®Google Scholar
• Dahiya N, Morin PJ. MicroRNAs in ovarian carcinomas. Endocr. Relat. Cancer17, F77–F89 (2010).
   PubMed Web of Science ®Google Scholar
• Laios A, O’Toole S, Flavin R et al. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol. Cancer7, 35 (2008).
   PubMed Web of Science ®Google Scholar
• Yang N, Kaur S, Volinia S. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res.68, 10307–10314 (2008).
   PubMed Web of Science ®Google Scholar
• Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA105, 10513–10518 (2008).
   PubMed Web of Science ®Google Scholar
• Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol. Oncol.112, 55–59 (2009).
   PubMed Web of Science ®Google Scholar
• Yang H, Kong W, He L et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res.68, 425–433 (2008).
   PubMed Web of Science ®Google Scholar
• Ye G, Fu G, Cui S. MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance. J. Cell Sci.124, 359–368 (2011).
   PubMed Web of Science ®Google Scholar
• Cochrane DR, Howe EN, Spoelstra NS, Richer JK. Loss of miR-200c: a marker of aggressiveness and chemoresistance in female reproductive cancers. J. Oncol.2010, 821717 (2010).
   PubMedGoogle Scholar
• Li Z, Hu, S, Wang et al. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol. Oncol.119, 125–130 (2010).
   PubMed Web of Science ®Google Scholar
• Djuranovic S, Nahvi A, Green R. A parsimonious model for gene regulation by miRNAs. Science331, 550–553 (2011).
   PubMed Web of Science ®Google Scholar
• Yasui K, Mihara S, Zhao C et al. Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res.64, 1403–1410 (2004).
   PubMed Web of Science ®Google Scholar
• Hooks SB, Callihan P, Altman MK, Hurst JH, Ali MW, Murph MM. Regulators of G-protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells. Mol. Cancer9, 289 (2010).
   PubMedGoogle Scholar
• Xu G, Zhong Y, Munir S, Yang BB, Tsang BK, Peng C. Nodal induces apoptosis and inhibits proliferation in human epithelial ovarian cancer cells via activin receptor-like kinase 7. J. Clin. Endocrinol. Metab.89, 5523–5534 (2004).
   PubMedGoogle Scholar
• Xu G, Zhou H, Wang Q, Auersperg N, Peng C. Activin receptor-like kinase 7 induces apoptosis through up-regulation of Bax and down-regulation of Xiap in normal and malignant ovarian epithelial cell lines. Mol. Cancer Res.4, 235–246 (2006).
   PubMedGoogle Scholar
• Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal.14, 381–395 (2002).
   PubMed Web of Science ®Google Scholar
• Abedini MR, Muller EJ, Bergeron R, Gray DA, Tsang BK. Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein. Oncogene29, 11–25 (2010).
   PubMedGoogle Scholar
• Chen JG, Horwitz SB. Differential mitotic responses to microtubule-stabilizing and destabilizing drugs. Cancer Res.62, 1935–1938 (2002).
   PubMed Web of Science ®Google Scholar
• Hetland TE, Hellesylt E, Florenes VA, Trope C, Davidson B, Kaern J. Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance. Hum. Pathol.42(7), 1019–1026 (2011).
   PubMed Web of Science ®Google Scholar
• Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol. Cancer Ther.8, 1055–1066 (2009).
   PubMed Web of Science ®Google Scholar